Loading
Drugs are processed differently by people with different genetic backgrounds, but doses are set mostly in white and East Asian populations. Every new drug should be studied for how it behaves across ancestries, with dosing advice by genotype rather than by race.
Registrational programmes include pharmacokinetic and pharmacogenomic sub-studies powered across the main genetic ancestry groups, genotyping known variants (CYP2D6, CYP3A5, UGT1A1, DPYD, NUDT15, HLA alleles) and reporting exposure and toxicity by genotype. Labels carry genotype-based dosing where exposure differs, replacing crude race-based statements. African, South Asian and Indigenous populations are prioritised because they are least represented in existing PK data.
Shares Wrong doses, Trials do not represent the people who get cancer.
Shares Wrong doses, Trials do not represent the people who get cancer.
Shares Trials do not represent the people who get cancer, Germline (hereditary) testing.
Shares Germline vs somatic mutations, Germline (hereditary) testing.
Shares Wrong doses, Germline (hereditary) testing.
Shares Germline vs somatic mutations, Germline (hereditary) testing.
Shares Germline vs somatic mutations, Germline (hereditary) testing.
Shares Germline vs somatic mutations, Germline (hereditary) testing.